Immunic Therapeutics Developing Selective Oral Drugs in Immunology NASDAQ: IMUX Piper Jaffray 31st Annual Healthcare Conference December 5, 2019 Cautionary Note Regarding Forward-Looking Statements • Certain statements contained in this presentation regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These include s ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Immunic, Inc. (Exact name of registrant as specified in its charter) FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36201 Delaware 56-2358443 (State or other jurisdiction o ...

| --- | --- | |--------------------|-----------------------------------------------------------------------------------| | | | | | | | | | | | Immunic Therapeutics Developing Selective Oral Drugs in Immunology NASDAQ: IMUX | | Ladenburg Thalmann | Healthcare Conference September 24, 2019 | Cautionary Note Regarding Forward-Looking Statements • Certain statements contained in this presentation regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21E of ...

| --- | --- | |-------|-----------------------------------------------------------------------------| | | | | | | | | | | | | | | Immunic Therapeutics Developing Selective Oral Drugs in Immunology | | | NASDAQ: IMUX 39th Annual Canaccord Genuity Growth Conference August 8, 2019 | Cautionary Note Regarding Forward-Looking Statements • Certain statements contained in this presentation regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (858) 673-6840 (Registrant's telephone number, including area code) Commission File Number: 001-36201 Immunic, Inc. (Exact name of registrant as specified i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36201 Vital Therapies, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36201 Vital Therapies, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...